Mail-In HPV test could boost cervical cancer screening

NCT ID NCT06674681

First seen Feb 01, 2026 · Last updated Jun 20, 2026 · Updated 19 times

Summary

This study aims to make cervical cancer screening more convenient by offering HPV self-collection kits that women can use at home or in the clinic. Researchers will enroll 1,000 women aged 25-65 who are overdue for screening. The goal is to see how many women complete the test and follow up on positive results, helping clinics adopt this approach more widely.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HPV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Utah Health Hospitals/Huntsman Cancer Institute Population Sciences

    RECRUITING

    Salt Lake City, Utah, 84112, United States

    Contact

    Contact Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

HPV self-collection kit

What this could lead to

If successful, this could make cervical cancer screening easier and more accessible, especially for women who are overdue.

What could go wrong

This is an implementation study, not a test of the test itself. It may not show a big impact on screening rates or follow-up care.

Conditions

The condition(s) this trial relates to.

human papilloma virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.